Refeyn announces that the company’s Chief Executive Officer, Anthony Fernandez, is stepping down as CEO for health reasons.
The announcement comes after Fernandez began a leave of absence from his role earlier this year. At the start of that period, Jean-Paul Mangeolle took on the role of interim CEO to support the business. He will continue in that position while Refeyn conducts an executive search for a permanent CEO to support the next phase of its growth.
“We wish Anthony all the best and thank him for his significant contributions to Refeyn’s success over the last two years. We expect him to make a full recovery and agree that his health must be his priority at this difficult time.” says Jonathan Flint, Chairman of Refeyn’s Board of Directors.
Mangeolle has been a member of the Refeyn board since August 2022 and has worked for over 35 years in the life sciences industry with Millipore and Merck, retiring recently from Danaher.